Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer

Neoplasia (United States)

Volumn 15, Issue 1, 2013, Pages 61-72

  Galvani, Elena ^a,b   Giovannetti, Elisa ^b   Saccani, Francesca ^a   Cavazzoni, Andrea ^a   Leon, Leticia G ^c   Dekker, Henk ^b   Alfieri, Roberta ^a   Carmi, Caterina ^a   Mor, Marco ^a   Ardizzoni, Andrea ^d   Petronini, Pier Giorgio ^a   Peters, Godefridus J ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLORO 4 FLUOROANILINO) 7 ETHOXYQUINAZOLINO DERIVATIVE; 4 ANILINOQUINOLINE 3 CARBONITRILE DERIVATIVE; CANERTINIB; CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; K RAS PROTEIN; PROPIONAMIDE DERIVATIVE; PROTEIN KINASE B; UNCLASSIFIED DRUG; UPR 1268; UPR 1282; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84873028467     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121434     Document Type: Article

References (50)

1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, and Piccirillo J (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28), 4539-4544.
2. Hoang T and Schiller JH (2002). Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy. Expert Rev Anticancer Ther 2(4), 393-401.
3. Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, et al. (2013). Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Curr Pharm Des 19(5), 818-832.
4. Olayioye MA, Neve RM, Lane HA, and Hynes NE (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19(13), 3159-3167.
5. Ciardiello F and Tortora G (2008). EGFR antagonists in cancer treatment. N Engl J Med 358(11), 1160-1174.
6. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, and Varmus H (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3), e73.
7. Suda K, Onozato R, Yatabe Y, and Mitsudomi T (2009). EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 4(1), 1-4.
8. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043.
9. Bean J, Brennan C, Shih J-Y, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al. (2007). MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52), 20932-20937.
10. Carmi C, Cavazzoni A, Vezzosi S, Bordi F, Vacondio F, Silva C, Rivara S, Lodola A, Alfieri RR, La Monica S, et al. (2010). Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. J Med Chem 53(5), 2038-2050.
11. Wu C-H, Coumar MS, Chu C-Y, Lin W-H, Chen Y-R, Chen C-T, Shiao H-Y, Rafi S, Wang S-Y, Hsu H, et al. (2010). Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency. J Med Chem 53(20), 7316-7326.
12. Cha MY, Lee K-O, Kim JW, Lee CG, Song JY, Kim YH, Lee GS, Park SB, and Kim MS (2009). Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer. J Med Chem 52(21), 6880-6888.
13. Ding K, Zhang L, Xu S, Luo J, Lu X, Xu T, Liu Y, Tu Z, Xu Y, Ren X, et al. (2012). Design, synthesis and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor T790M mutant. J Med Chem 55(6), 2711-2723.
14. Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Showalter HD, Vincent PW, Elliott WL, et al. (2000). Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino) quinazoline-and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem 43(7), 1380-1397.
15. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, et al. (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702-4711.
16. Wissner A, Overbeek E, ReichMF, FloydMB, Johnson BD, Mamuya N, Rosfjord EC, Discafani C, Davis R, Shi X, et al. (2003). Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. J Med Chem 46(1), 49-63.
17. Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, Amato DM, Nelson JM, et al. (2008). Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 7(7), 1880-1889.
18. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, and Sarkar FH (2009). Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69(6), 2400-2407.
19. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, and Kikkawa F (2007). Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31(2), 277-283.
20. Rho JK, Choi YJ, Lee JK, Ryoo B-Y, Na II, Yang SH, Kim CH, and Lee JC (2009). Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63(2), 219-226.
21. Jung M-J, Rho J-K, Kim Y-M, Jung JE, Jin YB, Ko Y-G, Lee J-S, Lee S-J, Lee JC, and Park M-J (2012). Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene. DOI: 10.1038/onc.2012.37, Epub ahead of print.
22. Carmi C, Galvani E, Vacondio F, Rivara S, Lodola A, Russo S, Aiello S, Bordi F, Costantino G, Cavazzoni A, et al. (2012). Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. J Med Chem 55(5), 2251-2264.
23. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82(13), 1107-1112.
24. Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R, et al. (2010). Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 9(3), 581-593.
25. Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, et al. (2011). Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 105(10), 1542-1553.
26. Alfieri RR, Galetti M, Tramonti S, Andreoli R, Mozzoni P, Cavazzoni A, Bonelli M, Fumarola C, La Monica S, Galvani E, et al. (2011). Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. Mol Cancer 10, 143.
27. Giovannetti E, LabotsM, Dekker H, Galvani E, Lind JSW, Sciarrillo R, Honeywell R, Smit EF, Verheul HM, and Peters GJ (2013). Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. Curr Pharm Des 19(5), 927-939.
28. Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ, and Giovannetti E (2012). Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther 11(8), 1735-1746.
29. Funel N, Vasile E, Del Chiaro M, Boggi U, Falcone A, Campani D, Scarpa A, and Giovannetti E (2011). Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. Ann Oncol 22(2), 482-484.
30. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15), 1960-1966.
31. Voulgari A and Pintzas A (2009). Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796(2), 75-90.
32. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, and Johnson KR (2008). Cadherin switching. J Cell Sci 121(pt 6), 727-735.
33. Dasari V, Gallup M, Lemjabbar H, Maltseva I, and McNamara N (2006). Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"? Am J Respir Cell Mol Biol 35(1), 3-9.
34. Chen Y-T, Gallup M, Nikulina K, Lazarev S, Zlock L, Finkbeiner W, and McNamara N (2010). Cigarette smoke induces epidermal growth factor receptor-dependent redistribution of apical MUC1 and junctional β-catenin in polarized human airway epithelial cells. Am J Pathol 177(3), 1255-1264.
35. Padrón JM, van der Wilt CL, Smid K, Smitskamp-Wilms E, Backus HH, Pizao PE, Giaccone G, and Peters GJ (2000). The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol 36(2-3), 141-157.
36. Reya T, Morrison SJ, Clarke MF, and Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature 414(6859), 105-111.
37. Eramo A, Haas TL, and De Maria R (2010). Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 29(33), 4625-4635.
38. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, et al. (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106(38), 16281-16286.
39. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21), 2129-2139.
40. Miksad RA, Schnipper L, and Goldstein M (2007). Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 25(28), 4506-4507. author reply 4508.
41. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C, et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19), 1817-1825.
42. Piersma SR, Labots M, Verheul HMW, and Jiménez CR (2010). Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. Anal Bioanal Chem 397(8), 3163-3171.
43. Uzawa K, Ishigami T, Fushimi K, Kawata T, Shinozuka K, Kasamatsu A, Sakamoto Y, Ogawara K, Shiiba M, Bukawa H, et al. (2011). Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells. Oncogene 30(43), 4447-4452.
44. Nakamoto M and Bergemann AD (2002). Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59(1), 58-67.
45. Infusino GA and Jacobson JR (2012). Endothelial FAK as a therapeutic target in disease. Microvasc Res 83(1), 89-96.
46. Forest V, Campos L, Vergnon J-M, Cornillon J, and Guyotat D (2005). Characterization of the focal adhesion complex in human non-small cell lung cancer cell lines. Anticancer Res 25(6B), 4135-4139.
47. Xiao D and He J (2010). Epithelial mesenchymal transition and lung cancer. J Thorac Dis 2(3), 154-159.
48. Fonseca FLA, Azzalis LA, Feder D, Nogoceke E, Junqueira VBC, Valenti VE, and de Abreu LC (2011). Adhesion molecules affected by treatment of lung cancer cells with epidermal growth factor. Lung 189(5), 383-389.
49. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, and Haley JD (2005). Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65(20), 9455-9462.
50. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, and Pirozzi G (2009). The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36(3), 446-453.